readthroughSign in
Nov 12, 2026Regulatory decision

FDA approves Biocon Biologics' Pebrilzo, a pertuzumab product

The agency cleared the biologics license application for Pebrilzo on November 12, 2026, with the label dated November 13, 2026.

The U.S. Food and Drug Administration approved Pebrilzo under Biologics License Application 761501, with a submission status date of November 12, 2026, according to FDA records. The sponsor of record is Biocon Biologics Inc.1

Pebrilzo is formulated as an injectable solution containing pertuzumab as its active ingredient, at a strength of 420 mg per 14 mL, or 30 mg per mL, per the FDA's drug database entry. The application was given a standard review priority and was filed as an original submission.1

The FDA's records list two application documents tied to the approval: a product label and an approval letter, both dated November 13, 2026. The label document is available at the agency's drug approvals portal, as is the corresponding approval letter.1

The filing is a biologics license application, the regulatory pathway the FDA uses for biologic products, which can include biosimilars, though the FDA record does not explicitly describe Pebrilzo using that term. The documents do not provide additional detail on the product's intended indications, dosing regimen, or any reference product comparison that would typically accompany a biosimilar filing. Readers seeking that information should consult the full prescribing label once it is publicly posted.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.